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Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of 
androgen receptor variant 7 in prostate cancer cells. 
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Abstract 
 
Resistance to available hormone therapies in prostate cancer has been 
associated with alternative splicing of androgen receptor (AR), and 
specifically, the expression of truncated and constitutively active AR variant 7 
(AR-V7). The transcriptional activity of steroid receptors, including AR, is 
dependent on interactions with the HSP90 chaperone machinery, but it is 
unclear if HSP90 modulates the activity or expression of AR variants. Here, 
we investigated the effects of HSP90 inhibition on AR-V7 in prostate cancer 
cell lines endogenously expressing this variant. We demonstrate that AR-V7 
and full-length AR (AR-FL) were depleted upon inhibition of HSP90. However, 
the mechanisms underlying AR-V7 depletion differed from those for AR-FL. 
Whereas HSP90 inhibition destabilized AR-FL and induced its proteasomal 
degradation, AR-V7 protein exhibited higher stability than AR-FL and did not 
require HSP90 chaperone activity. Instead, HSP90 inhibition resulted in the 
reduction of AR-V7 mRNA levels, but did not affect total AR transcript levels, 
indicating that HSP90 inhibition disrupted AR-V7 splicing. Bioinformatic 
analyses of transcriptome-wide RNA sequencing data confirmed that the 
second-generation HSP90 inhibitor onalespib altered the splicing of at least 
557 genes in prostate cancer cells, including AR. These findings indicate that 
the effects of HSP90 inhibition on mRNA splicing may prove beneficial in 
prostate cancers expressing AR-V7, supporting further clinical investigation of 
HSP90 inhibitors in malignancies no longer responsive to androgen 
deprivation. 
 
Keywords: prostate cancer, HSP90, onalespib, AR-V7, splicing 
 
Precis: A novel mechanism of action for HSP90 inhibitors involving the 
suppression of androgen receptor splicing strengthens predictions that these 
therapeutics may elicit potent clinical responses in advanced prostate 
cancers. 
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Introduction  
Prostate cancer is the most common cancer in men and a leading cause of 
male cancer mortality in Western societies (1). Androgen deprivation remains 
the mainstay of treatment for patients with advanced stage disease. However, 
the response to suppression of gonadal androgens is not durable and 
transition of metastatic disease to a lethal castration-resistant prostate cancer 
(CRPC) is inevitable. It is now widely recognized that CRPC progression 
results from many different alterations of the androgen/AR axis that promote 
continued androgen receptor (AR) transcriptional activity.  Novel androgen 
biosynthesis inhibitors (e.g. abiraterone acetate) and AR antagonists (e.g. 
enzalutamide) overcome several of the mechanisms underlying persistent AR 
transcriptional activity, and have been shown to extend overall survival of 
patients with CRPC (2, 3).  
AR belongs to the nuclear receptor super family of transcription factors whose 
members are ligand-responsive transcription factors. The AR gene is located 
on Xq11–12; it contains eight exons that encode a protein of 919 amino acids 
(AR-FL). It is composed of four functional domains: the amino-terminal 
transcription activation domain (NTD), which possesses a ligand-independent 
transcriptional function (AF-1); the DNA-binding domain (DBD), which binds to 
specific DNA sequences named androgen-responsive elements (ARE); the 
hinge region, which includes a part of the nuclear localization signal; and the 
carboxy-terminal ligand-binding domain (LBD), which has a ligand-dependent 
transcriptional activity (AF-2). Multiple alternatively spliced AR variants (AR-V) 
have been identified and translated from alternatively spliced AR mRNAs (4). 
These variants typically contain exons 1-3, but lack portions of the carboxy-
terminal LBD, and may be constitutively active (5, 6). AR-Vs have been 
shown to drive androgen-independent cell proliferation in a manner that is 
resistant to antiandrogens, including enzalutamide (7). The expression of AR-
Vs is higher in CRPC compared to primary hormone-naïve prostate cancer 
and is reported to be mostly lacking in normal prostate epithelium (5, 6, 8-11). 
Constitutively active AR-Vs have been implicated as a mechanism of 
resistance to current hormonal therapies targeting the LBD (7, 12-15). 
One of the best characterized variants, and the most frequently detected in 
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CRPC to date (11), is the AR-V7 (also termed AR3), which contains exons 1–
3 and 16 unique amino acids that arise from cryptic exon 3 (6). AR-V7 
localizes constitutively to the nucleus, and facilitates AR-FL nuclear 
localization in the absence of androgen (14). AR-V7 upregulation mitigates 
the ability of the AR antagonist enzalutamide to inhibit AR-FL nuclear 
trafficking (14). AR-V7 may also direct a distinct transcriptional program to 
AR-FL, including the transcription of several cell-cycle-related genes in 
addition to canonical androgen-responsive genes (11, 16). Recent clinical 
studies have linked AR-V7 expression in circulating tumor cells (CTC) and 
CRPC tissue with resistance to enzalutamide and abiraterone (17, 18). This 
highlights an urgent need for alternative treatment strategies targeting AR-Vs. 
HSP90 is a molecular chaperone essential for the late stage maturation, 
stability and function of a large number of client proteins involved in key signal 
transduction pathways in prostate cancer, including AR, AKT and the 
glucocorticoid receptor (GR) (19-21). A key requirement for the transcriptional 
activity of steroid receptors is the interaction of unbound receptor with the 
HSP90 chaperone machinery. This interaction occurs exclusively through the 
LBD via direct binding to HSP40 and HSP70 (22, 23). In prostate cancer cells 
inhibition of HSP90 chaperone activity impairs the nuclear translocation of 
AR-FL and enhances the degradation of AR-FL protein resulting in decreased 
AR-FL transcriptional output (20, 24, 25) and prostate cancer cell proliferation 
(26, 27). Conversely, recent studies have suggested that AR-V7 nuclear 
translocation and transcriptional activity does not require HSP90 activity (28, 
29) although HSP90 has been proposed as a therapeutic target in CRPC.  
Several HSP90 inhibitors are undergoing clinical trial (29, 30). In this study, 
we investigated the effect of HSP90 inhibition in prostate cancer cells 
expressing AR-V7. We demonstrate that HSP90 inhibition reduces expression 
of AR-V7. Interestingly, we show that AR-V7 down-regulation is not due to a 
traditional client-chaperone mechanism but results from disruption of AR 
splicing following HSP90 inhibition.  
 
Methods 
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Cell lines and drug treatment 
22Rv1 (#CRL-2505), VCaP (#CRL-2876) and PC3 (#CRL-1345) cells were 
obtained from the American Type Culture Collection (ATCC) and grown in 
their recommended culture medium, containing 10% FBS at 37°C in an 
atmosphere of 5% CO2.  LNCaP95, an androgen-independent cell line 
derived from long-term continuous culture of LNCaP cells, were cultured in 
red-phenol free RPMI-1640 supplemented with 10% charcoal-stripped FBS 
(CSS; Invitrogen). Tanespimycin (17-AAG; LC Laboratories), alvespimycin 
(17-DMAG; LC laboratories), R1881 (Steraloids), geldanamycin (Stratech), 
MG132 (Sigma-Aldrich), actinomycin D (Sigma), and cyclohexamide (Sigma) 
were obtained from commercial sources. Lactate salt of onalespib (AT13387) 
was synthesized by Astex Pharmaceuticals according to Woodhead et al (31).  
Cell growth inhibition 
Cell growth inhibition was assessed using the sulforhodamine B assay (SRB)  
(32). The GI50 was calculated as the drug concentration that inhibits cell 
growth by 50% compared with control growth using GraphPad Prism 
software. 
Cell-cycle analysis 
Cell cycle distribution and sub-G1 populations were analyzed by flow 
cytometry using propidium iodide staining (33).  Data were analysed with the 
Flowjo Software. 
Cell lysis and Western blot analysis 
Whole cells were lysed in RIPA buffer (Pierce) supplemented with protease 
inhibitor cocktail (cOmplete, Roche). The nuclear and cytosolic subcellular 
fractions were prepared using the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Pierce) according to manufacturer’s instructions. To obtain 
detergent-soluble and detergent-insoluble fractions cells were lysed in TNESV 
buffer (1% NP40 detergent, 0.5% deoxycholate, 50 mM Tris–Cl (pH 7.4), 150 
mmol/L NaCl, 0.5 mmol/L EDTA) for 20 min on ice. The NP40 detergent-
insoluble pellet fraction was resuspended in RIPA lysis buffer with protease 
inhibitors by brief sonication. Protein extracts (20 μg) were separated on 4-
12% NuPAGE® Bis-Tris gel (Invitrogen) by electrophoresis and subsequently 
electro-transferred onto Immobilon-P™ PVDF membranes of 0.45 μm pore 
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size (Millipore). Details of primary antibodies used are provided in 
Supplementary Table 1.  Chemiluminescence was detected on Amersham 
Hyperfilm ECL (GE Healthcare Life Science). In some experiments the 
FluorChem™ Q Imager and Software was used for annotation and analysis of 
images including densitometry.  
Reverse transcription and quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted from cells using the RNeasy® Plus Mini kit (Qiagen) 
and from formalin-fixed and paraffin-embedded (FFPE) tissue using the 
RNeasy FFPE kit (Qiagen) as per manufacturer’s instructions. 5 µl of RNA 
was reverse-transcribed into cDNA using the First Strand cDNA Synthesis Kit 
(Roche). Quantitative real-time PCR (qRT-PCR) was carried out on on ViiA™ 
7 System Real-Time PCR System (Life Technologies) using the TaqMan® 
Universal PCR Master Mix (Applied Biosystems). The assays used in this 
study are listed in Supplementary Table 2. Fold change in mRNA expression 
levels was calculated by the comparative Ct method, using the formula 2-(-
(Ct) and Human RPLPO (Large Ribosomal Protein) as calibrator. The 
vehicle-treated sample was set to 1.  
Co-immunoprecipitation 
Whole cell lysates were obtained using Pierce IP Lysis buffer (Thermo 
Scientific). Protein extracts (approximately 1 mg of total protein) were pre-
cleaned by protein A/G Plus-agarose (Millipore) and extracts were incubated 
with the respective antibodies (1 μg) overnight at 4 °C. Immune complexes 
were collected by protein A/G Plus-agarose beads, analyzed by 
immunoblotting, probed with the protein A/G HRP-conjugated secondary 
antibody (Thermo Scientific), and visualized using an ECL 
chemiluminescence (Thermo Scientific).  
Transfection  
PC3 cells (3x105) were plated on 6-well plates and reverse transfected using 
the X-tremeGENE HP DNA Transfection Reagent (3 µl per well; Roche) (34).  
The plasmid constructs (1 µg DNA per well) used were pcDNA3.1-AR-V7 
(encoding the V7 truncated AR isoform, a gift from Dr Jun Luo, Johns Hopkins 
University, Baltimore, USA), and F527-AR (encoding the full-length AR) (34). 
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Tumor xenograft studies  
Subcutaneous 22Rv1 solid tumor xenografts were prepared by serial 
passaging in male NMRI nu/nu mice (Harlan). Tumors were measured twice 
weekly with micro-calipers and tumor volumes determined using the formula: 
(length x breadth2 x 0.5). Drug treatment was started when tumors were well 
established (mean tumor volume 120 mm3). Onalespib was dissolved in 
17.5% (w/v) hydroxypropyl-β-cyclodextrin and administered intraperitoneally 
at 70 mg/kg twice a week for 2 weeks or 80 mg/kg once weekly (35).  For 
pharmacodynamic analyses, tumor-bearing animals were sacrificed at 
indicated time points after a single dose of onalespib at 80 mg/kg (typically 4 
per time point).  
 
Immunohistochemistry  
Immunohistochemistry (IHC) for AR N-terminus domain (AR-NTD), HSP72, 
Ki67 and cleaved caspase 3 was performed on 4 µm FFPE tumor sections. 
Details of the IHC assays are provided in Supplementary Table 3. Slides 
were counterstained with hematoxylin (TCS Biosciences Ltd), dehydrated, 
and mounted with DPX mountant (Sigma). All sections were scored by a 
pathologist blinded to treatment information.  
RNA-Sequencing (RNA-Seq)  
Total cellular RNA was extracted and purified using the RNeasy Mini Kit 
(Qiagen). RNA integrity was determined by Bioanalyzer 2100 (Agilent 
Technologies) and only samples with a RNA Integrity Numbers ≥9.5 were 
used. 500 ng of RNA was prepared into a library using the TruSeq RNA 
sample prep kit v2 (Illumina), and then clustered and sequenced on a Hi-Seq 
2000 (Illumina) using TruSeq v3. An average of around 40 million paired end 
reads were sequenced per sample. The experiment was repeated three 
times. The paired end raw reads in FASTQ format were aligned to the 
reference human genome (hg19) using TopHat v2.0.7. The library and 
mapping quality were estimated using Picard tools 
(http://broadinstitute.github.io/picard). The alternative splicing events (SE, RI, 
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MXE, A5SS and A3SS), based on Ensembl v61 annotation, were accessed 
using MATS v3.0.8 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333886/).  
Statistical analyses 
Effects of different treatments were compared using the Student’s t test, 
Mann–Whitney test or ANOVA.  Survival analysis was performed by Kaplan–
Meier methods and log-rank analysis using quadruplication of the tumor as 
surrogate endpoint. In the RNA-seq analysis, the supportive reads of each 
alternative splicing event were counted, with the inclusion level being 
estimated using a Bayesian model as described by Shen et al., 2012 (36). 
Pairwise comparisons of each splicing event were performed among 
treatments using the Markov chain Monte Carlo method coupled with a 
simulation-based adaptive sampling procedure to calculate the p-value (36). 
Sample replicates were used to control variability within-treatment groups. 
The false discovery rate (FDR) was obtained by the Benjamini-Hochberg 
method with a FDR <0.05 being employed for the differential alternative 
splicing significance assessment.  
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Results 
HSP90 targeting inhibits proliferation of prostate cancer cells 
expressing AR-V7 
We initially examined the effects of the first-generation HSP90 inhibitors 
tanespimycin (17-AAG) and alvespimycin (17-DMAG) and the second-
generation HSP90 inhibitor onalespib (AT13387) on cell proliferation in human 
prostate cancer cell lines expressing the AR-V7 including 22Rv1, VCaP and 
LNCaP95. Previous studies had established the expression status for both 
AR-FL and AR-Vs in these cell lines (5, 6, 28). HSP90 inhibition reduced cell 
proliferation in a dose-dependent manner (data not shown). Onalespib and 
alvespimycin potently inhibited the growth of the androgen-dependent cell line 
VCaP, and also the growth of the androgen-independent 22Rv1 and 
LNCaP95 cell lines, which are resistant to the AR antagonist enzalutamide (7, 
11) (Table 1). Our results confirmed previous observations that AR-V7 
expression does not confer resistance to HSP90 inhibitors in prostate cancer 
cells (29).  
HSP90 targeting depletes AR-FL and AR-V7 in prostate cancer cell lines  
We then investigated the effect of HSP90 inhibition on AR-FL and AR-V7 
protein levels in prostate cancer cells expressing both the AR-FL and AR-V7. 
Onalespib reduced AR-FL protein irrespective of AR-FL status (i.e. wild-type 
or mutant), in a concentration- and time-dependent fashion in VCaP and 
22Rv1 cell lines (Figure 1)  Notably, onalespib caused similar depletion of 
AR-V7 protein in the 3 cell lines tested (Figure 1). AR-FL and AR-V7 
depletion was accompanied by a concentration-dependent (data not shown) 
and time-dependent depletion of various HSP90 clients including AKT, 
ERBB2, CRAF and GR (Supplementary Figure 1). HSP72 and HSP27 were 
induced by HSP90 inhibition, associated with the heat shock factor-1 (HSF-1)-
mediated stress response, confirming HSP90 target engagement (37). Similar 
results were observed with first generation HSP90 inhibitors (geldanamycin, 
tanespimycin, alvespymycin); however  tanespimycin resulted only in modest 
depletion of AR-FL and AR-V7 at the concentrations used in VCaP and 22Rv1 
cells (Supplementary Figure 2 and 3). Since DT-diaphorase/NQO1 plays a 
role in primary and acquired resistance to tanespimycin (32, 38), we 
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evaluated constitutive protein expression levels in prostate cancer cell lines to 
clarify if lower sensitivity to tanespimycin was due to different expression of 
the enzyme. Low levels of DT-diaphorase/NQO1 protein were detected in 
22Rv1 and VCaP cells, respectively by immunoblotting, possibly explaining 
the differences in effect seen with tanespimycin compared to alvespimycin 
and onalespib (data not shown). We should note that all the HSP90 inhibitors 
we had tested inhibit both alpha and beta HSP90 isoforms.  We confirmed 
depletion of AR-V7 protein when the expression of both the HSP90 isoforms 
was reduced simultaneously by siRNA knockdown (Supplementary Figure 
4).  
Importantly, in time-course experiments, the kinetics of AR-V7 protein loss in 
response to HSP90 inhibition differed from that for AR-FL (Figure 1C and 
1D). Onalespib induced a reduction of AR-FL protein within 4 hours. In VCaP 
cells AR-FL was reduced in a time-dependent fashion with maximal depletion 
reached at 48-72 hours, but in LNCaP95 AR-FL protein level remained 
constant. Depletion of AR-V7 was first noted after 12-24 hours reaching 
maximal depletion at 48-72 hours, when AR-V7 was hardly detectable. The 
timing and degree of AR-V7 depletion was similar in VCaP and LNCaP95. 
These results confirmed AR-FL depletion following HSP90 inhibition and also 
indicated for the first time that AR-V7 protein level is also decreased when 
HSP90 is inhibited.  
 
AR-V7 protein is more stable than AR-FL and is not directly affected by 
HSP90 inhibition  
HSP90 inhibition results in protein client destabilization and degradation by 
the ubiquitin-proteasome pathway (39). Ubiquitinated proteins first accumulate 
in the cytosol and become aggregated and relocated in the detergent-
insoluble fraction of cells when proteasomes are inhibited. To evaluate 
whether AR-V7 protein depletion was due to increased proteasomal 
degradation after HSP90 blockade, we examined the impact of the 
proteasome inhibitor MG132 on AR-V7 depletion by onalespib. VCaP cells 
were treated with onalespib in the presence or absence of proteasome 
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inhibitor MG132 for 24 hours. As expected, addition of MG132 to onalespib 
treatment induced accumulation of high-molecular weight ubiquitinated AR-FL 
forms that were redistributed to the detergent-insoluble fraction (Figure 2A).  
Such accumulation of high-molecular weight AR-V7 forms was not observed, 
suggesting the lack of involvement of the proteasomal pathway in AR-V7 
depletion by onalespib (Figure 2A). 
To determine whether the observed decrease in AR-V7 protein in onalespib-
treated cells was the result of altered protein stability, we treated VCaP with 
the protein synthesis inhibitor cycloheximide (CHD) in the presence or 
absence of onalespib (Figure 2B and 2C). When protein synthesis was 
inhibited by CHD, AR-V7 stability was greater than AR-FL (Figure 2B) 
suggesting that AR-V7 has a longer half-life than AR-FL. Onalespib treatment 
significantly reduced AR-FL protein levels, indicating increased degradation of 
AR-FL (Figure 2B and 2C top panel). Conversely, AR-V7 protein stability 
was not affected as demonstrated by similar levels of AR-V7 in the presence 
of onalespib (Figure 2B and 2C bottom panel). To further confirm that the 
effect of onalespib was not due to protein destabilization and increased 
protein degradation, we also investigated the effects of onalespib in the AR-
negative PC3 cell line transiently transfected with plasmid constructs carrying 
AR-FL and AR-V7 cDNA. Onalespib treatment in this transient transfection 
system resulted in depletion of transiently-expressed AR-FL but not AR-V7 
protein, confirming that the effect of HSP90 inhibition on AR-V7 was not due 
to destabilization or a direct effect on AR-V7 protein (Supplementary 
Figure5).  
AR-V7 bypasses direct HSP90 binding 
A key requirement for steroid receptor activity is the interaction of unliganded 
receptors with the HSP90 chaperone machinery (40). To further examine the 
relationship between AR-V7 and HSP90, we determined by co-
immunoprecipitation assays whether AR-V7 and HSP90 protein complexes 
exist in prostate cancer cells that endogenously express the variant (Figure 
2D). As expected, AR-FL formed a complex with HSP90 when the cells were 
cultured in androgen-depleted media (Figure 2D top panel). In contrast, AR-
V7 did not co-immunoprecipitate detectable amounts of HSP90 (Figure 2D 
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bottom panel). This was in agreement with results of Gills et al. in PC3 cells 
exogenously expressing the AR-V7 (29). Also, in keeping with a previous 
report (7), using subcellular fractionation we confirmed that AR-V7 entered the 
nucleus independently of HSP90 activity (data not shown). Taken together, 
these results indicated that AR-V7 protein, unlike AR-FL, does not require 
HSP90 chaperone.   
HSP90 inhibition induces AR-V7 mRNA downregulation 
To evaluate whether AR-V7 depletion was due to down-regulation of AR 
mRNA expression we next examined levels of AR transcripts following 
onalespib treatment (Figure 3A). In VCaP, 22Rv1 and LNCaP95 cells treated 
for 24 hours with onalespib, AR-FL mRNA levels were not significantly altered 
(data not shown).  AR-V7 mRNA levels, however, were significantly 
decreased by onalespib in a concentration-dependent fashion (Figure 3A, 
Supplementary Figure 6). Onalespib treatment at 0.6 µmol/L for 48 hours 
decreased AR-V7 mRNA level by 72 % (Figure 3A).  To distinguish between 
transcriptional and post-transcriptional effects on AR-V7 mRNA we examined 
the effect of onalespib treatment on mRNA stability. VCaP cells were treated 
with onalespib or vehicle in combination with the transcriptional inhibitor 
actinomycin D (ACTD). Onalespib treatment did not significantly alter the AR-
V7 (Figure 3B) and AR-FL (data not shown) mRNA levels in the presence of 
ACTD, suggesting that the decrease in AR-V7 mRNA in onalespib-treated 
cells was not due to reduced stability of the mRNA.   These results, coupled 
with the lack of depletion of AR-FL mRNA, suggested that onalespib reduced 
the generation of AR-V7 mRNA. To test this, we evaluated levels of unspliced 
AR pre-mRNA in 22Rv1 cells using three different sets of primers/probes (AR-
5; AR-6; AR-7 Supplementary Table 2) directed against different regions of 
the unspliced AR cDNA (intron8-exon9; intron 3; exon2-intron2). Onalespib 
did not reduce levels of unspliced AR and AR-FL but only AR-V7 mRNA 
levels (Figure 3C) suggesting that HSP90 inhibition specifically altered pre-
mRNA splicing and impaired the generation of AR-V7 mRNA.  
HSP90 inhibition disrupts alternative splicing in prostate cancer cells  
HSP90 inhibition elicits a dual effect in cells: The depletion of client proteins 
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and the activation of a Heat Shock Response (HSR) mediated by HSF1) 
activation (41). It has been reported that the splicing of mRNA precursors is 
broadly repressed on heat shock (42-44). To evaluate global changes in 
splicing pattern associated with HSP90 inhibition we treated VCaP cells with 
onalespib (0.3 and 0.6 µmol/L) for 24 hours and performed RNASeq analysis. 
The two different concentrations of onalespib (0.3 and 0.6 µmol/L) resulted in 
largely overlapping splicing changes (Supplementary Table 4 and Figure 
4A). Onalespib treatment introduced 743 alternative splicing events involving 
557 genes (FDR <0.05) (Supplementary Table 4). In keeping with data 
following heat shock we observed a significant increase in the retention of 
introns in transcripts and decreased exon skipping (42, 43) (Figure 4 C). 
Furthermore, RNAseq analyses confirmed a reduction of AR-V7 cryptic exon 
expression (Figure 4B). Pathway analyses showed that genes involved in 
splicing, including processing of Capped Intron-Containing Pre-mRNA(R) and 
Spliceosome(K), as well as heat shock related pathways, were significantly 
enriched (FDR <0.05) in the alternative splicing events induced by HSP90 
inhibition (Supplementary Table 5).  
 
Onalespib exhibits antitumor activity against AR-V7-expressing 22Rv1 
tumor xenografts 
We next evaluated the effect of onalespib on tumor growth and AR-V7 levels 
in 22Rv1 subcutaneous solid tumor xenografts. Onalespib was administered 
intraperitoneally at 70 mg/kg in a twice a week schedule (35).  Onalespib 
reduced tumor growth significantly when administered twice a week (P < 
0.001 against the vehicle control; Figure 5A) and significantly prolonged 
survival (Figure 5B). Weekly treatment at 80 mg/kg did not show significant 
benefit, suggesting that more frequent dosing is required in this fast growing 
model (data not shown). A single administration of onalespib at 80 mg/kg 
caused increases in cleaved caspase 3 and wide areas of necrosis together 
with reduced Ki67 expression were observed 48 and 72 hours after drug 
administration (Figure 5C). Reduction in total AR as assessed by an antibody 
directed against the AR-NTD was observed (Supplementary Figure 8). After 
a single dose of onalespib AR-V7 mRNA were reduced by 20% after 6 and 24 
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hours (P<0.05) (Figure 5D) while AR-FL levels were not significantly altered 
(Figure 5E). Levels of mRNA at 48 and 72 hours after drug administration 
were not evaluated due to the low amount and poor quality of RNA extracted 
from these tumors in which significant tumor cell kill and necrosis was 
observed (Figure 5C). Onalespib treatment also significantly downregulated 
PSA expression in tumors 24 hours following treatment (Supplementary 
Figure 7). Upregulation of HSP72 mRNA and protein by IHC confirmed 
HSP90 target engagement (Figure 5F and Supplementary Figure 8 and 9).  
 
Discussion  
In this study we examined the effects of HSP90 inhibition in prostate cancer 
cell lines expressing the AR-V7 variant. In vitro, the first-generation HSP90 
inhibitors tanespimycin and alvespimycin and the second-generation HSP90 
inhibitor onalespib induced cell growth inhibition and degradation of client 
proteins including AR-FL, AKT and GR. For the first time we demonstrated 
that the truncated splice variant AR-V7 protein is depleted when HSP90 is 
inhibited. Our results confirmed that AR-V7 protein, unlike AR-FL, does not 
require the HSP90 chaperone for its function and suggested that the 
mechanism underlying AR-V7 depletion upon HSP90 blockade was not 
directly linked to interaction of AR-V7 protein with the HSP90 chaperone. We 
demonstrated that AR-V7 mRNA levels were downregulated when HSP90 
was inhibited in a concentration-and time-dependent fashion.  Previous 
studies have linked heat shock to widespread but selective repression of 
splicing (42, 43). We therefore hypothesized that the heat shock response 
induced by HSP90, through the release of HSF1, can similarly broadly impact 
alternative splicing. We have shown that onalespib treatment introduced 743 
alternative splicing events involving 557 genes. In keeping with published data 
evaluating the impact of heat stress we observed a significant increase in 
retention of introns in transcripts and decreased exon skipping (42, 43). 
Pathway analyses showed that genes critically important to splicing, including 
processing of capped intron-containing pre-mRNA and spliceosome genes, as 
well as heat shock related pathways were significantly enriched in the 
alternative splicing events induced by HSP90 inhibition.    
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Further studies are required to elucidate the complex and multiple 
mechanisms that can underlie the alternative splicing disruption observed 
upon HSP90 inhibition. A previous study identified the serine/arginine-rich 
(SR) splicing factors U2AF65 and ASF/SF2 as critical to AR-V7 splicing (45).  
The function of SR splicing factors is regulated by their complex interaction 
with kinases, including the SR protein kinases (SRPKs) and Clk/Sty, as well 
as phosphatases that regulate their phosphorylation status (46). SRPK1 
interacts with various chaperones and co-chaperones including HSP70, 
HSP40 and Aha1 (47). Alternative splicing is also extensively regulated by 
signal transduction pathways, whereby signalling cascades can link the 
splicing machinery to the exterior environment (48, 49). HSP90 is heavily 
involved in the function of key nodes in these pathways.  For instance, AKT 
can directly phosphorylate SR proteins (50) or indirectly regulate SR protein 
by activating SRPK (51).  In addition, repression of splicing following heat 
stress has been related to the SR protein SRp38 dephosphorylation by the 
phosphatase PP1 (52, 53). 
Other groups have evaluated the effect of HSP90 inhibition on AR-V7 function 
and activity. Shafi et al. used LNCaP stably transfected with AR-V7 cDNA and 
demonstrated no effect on AR-V7 protein levels (54). Gillis et al. 
demonstrated that AR-V7 transcriptional activity is not altered by HSP90 
inhibition in PC3 cells transfected with prespliced AR-V7 driven by an ARR2-
probasin-luciferase (29). They also demonstrated AR-V7 does not bind 
HSP90 by co-immunoprecipitation using a FLAG-tagged AR-V7 transfected in 
PC3 cells. Our results in cell lines with endogenous AR-V7 support these 
observations. However, Gills et al. also reported that treatment of VCaP cells 
with the second-generation HSP90 inhibitors, luminespib (AUY922) and 
HSP990, increased AR-V7 protein (29) and Shafi et al reported no effect of 
geldanamycin on AR-V7 in 22Rv1 cells (54). Their results are incongruent 
with what we have observed with different HSP90 inhibitors in three prostate 
cancer cell lines expressing the AR-V7 (VCaP, LNCaP95 and 22Rv1).  
In conclusion, our observations confirm that AR-V7 protein functions 
independently of HSP90, and that AR-V7 is not a direct HSP90 client (29). 
However, we have demonstrated for the first time that HSP90 inhibition leads 
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to the depletion of AR-V7 protein by downregulating AR-V7 mRNA splicing. 
AR-V7 splicing was decreased by HSP90 inhibition in prostate cell lines 
resistant to androgen depletion and enzalutamide, suggesting that HSP90 
inhibition remains a viable approach to block the generation and possibly the 
upregulation of AR-V7 in CRPC.  Our data demonstrate a novel mechanism of 
action for this class of drugs in prostate cancer cells. Onalespib and other 
HSP90 inhibitors are now being tested in Proof of Concept clinical trials (29, 
30). These have included a Phase I study of onalespib in combination with 
abiraterone acetate in patients no longer responding to abiraterone 
(ClinicalTrials.gov Identifier: NCT01685268) (55). The impact of HSP90 
inhibitors on not only AR-FL and AR-V7, but also AKT and GR, makes HSP90 
inhibitors a class of drugs that merit further evaluation against metastatic 
prostate cancer.   
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